CA1256380A - Andreogen agent for application to the skin for body hair growth and enhancement of vitality in males - Google Patents
Andreogen agent for application to the skin for body hair growth and enhancement of vitality in malesInfo
- Publication number
- CA1256380A CA1256380A CA000496832A CA496832A CA1256380A CA 1256380 A CA1256380 A CA 1256380A CA 000496832 A CA000496832 A CA 000496832A CA 496832 A CA496832 A CA 496832A CA 1256380 A CA1256380 A CA 1256380A
- Authority
- CA
- Canada
- Prior art keywords
- androgen
- agent
- hair
- vitality
- acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
An androgen agent consisting essentially of androgen, adrenocortical hormone, and vitamin B2 of very low concentra-tions in an ointment base is very effective for the growth of hair on human bodies and increasing vitality in males with no skin inflammation without accumulation in cutaneous tissue and with no adverse side effects.
An androgen agent consisting essentially of androgen, adrenocortical hormone, and vitamin B2 of very low concentra-tions in an ointment base is very effective for the growth of hair on human bodies and increasing vitality in males with no skin inflammation without accumulation in cutaneous tissue and with no adverse side effects.
Description
~25638~
The present invention relates to an androgen agent for growing hair on the human body and increasing vitality in males.
It is an established theory that the growth of all body hair such an eyebrows, mustaches, and underarm hair, ex-cluding hair on the head is primarily controlled by androgens and does not grow very long. Further hair on the head is primarily controlled by estrogens and grows to great lengths.
It is also known that while there are baldheaded men there are few baldheaded women from natural causes. Further the reason why body hair is thick on males and thin on females is explainable by such hormonal action. In addition, it is also well known that male vitality can be increased by replenishing androgens.
As such, several agents for growing body hair consis--ting mainly of androgens have been marketed. However, all such agents cause skin inflammation.
Medical treatments have often been carried out to enhance the vitality of males by injecting high-ur,i-ts of andro-gen or by topical application. It is however now cornmon that strong adverse side effects occur in injection of the high-unit androgens and topical application thereof causes skin inflam-mation.
Further, by using androgens for both body hair growth and as vitality increasing agents, an effect is recognized because highly concentrated androgen agents are used. Ilowever, adverse side effects or skin inflammation due to the high con-centration of the androgen is inevitable.
The present invention provides an androgen agent w'nich has an excellent effect in increasing a body hair growth in humans and vitality in males with no significant adverse side effects and causes no significant skin inflammation as the androgen is Fed into the skin.
- 1 - ,~r~
~2 5~3 ~
According to the present invention therefore -there is ; provided an androgen agent for dermatological application for growing hair on the human body and/or increasirlg its vitality which cornprises per 100 9 of an ointment base up to 20 mg of androgen; up to 20 nlg of an adrenocortical hormone and up to 20 mg of vitamin B2.
The present invention is based on the concept that androgen is a generic nalne for hormones, in particular testosterone, secreted from the testicles which promote the growth of the male reproductive organs and has secondary sexual character, namely they have an androgenic activity. Testoster-one propionate, methyltestosterone and Fluoxymesterone are synthetic derivatives of testerone and all have androgen activity.
It is now considered by the inventor that the androgen has a body hair generating activity as well as the androgen activity described above. Thus body hair generation is a live body phenomenon controlled by androgens in the cutaneous tissue system, and is required for hair to grow from proteins to arrange to cultivating conditions while maintaining the normal living conditions of the cutaneous tissue system.
As in my prior invention as disclosed in my copending Canadian Patent Application Serial No. 459,176 which is directed to the development of hair on the head I have found tha-t the following three conditions are required for the development of hair on the body; (1) not only to replenish androgen to -the body, but also to reduce the concentration of androgen until no skin inflarnmation occurs and there are no other bad side effects due to its accumulation in the body; (2) to reduce the inflam-matory action of the androgen by the action of andrenocortical hormone; and (3) to apply~the metabolism of vitamirl B2 to the grow-th of hair from protein. I-t has thus been found when an ' ~ S ~3~ ~
androgen agent satisfying these three conditions is applied to the skin to generate hair on the body, that good hair develop-ment occurs with no skin inflammation.
For replenishing androgen onto the skin For enhancing . male vitality, it has been found that such an effect occurs without adverse side effects and without skin inflalnmation, when the conditions under which androgen acts is as aforesaid for hair development on the human body namely healthy living condi-tions of -the skin tissue. The androgen agent was evaluated by deterlnining the development of pubes as well as by investiga-ting the increase vitality of males by applying the androgen agent locally to the skin of a male. It was found -that the agent is very good in enhancing vitality with no adverse side effects and skin inflammation.
Adrenocortical hormones are hormones secreted from the adrenal cortex including prednisolone acetate, cortisone acetate, hydrocortisone acetate, methylprednisolone acetate, and prednisolone sodium succinate, all of which, excep-t aldosterone, have antiphlogistic action.
In one embodiment of the present invention an androgen agent for use in growing body hair and increasing vitality in males according to the present invention is prepared by uni~
formly distributing 1 mg of testosterone propionate (androgen), 1.1 mg of prednisolone acetate (andrenocortical hormone), 0.5 mg of riboflavine phosphate (vitamin B2 compound), 0.01 mg of falvine-adenine dinucleotide (vitarnin B2 compound), 0.3 mg of chlorophenylamine maleate, 1.0 mg of pyridoxine hydrochloride,
The present invention relates to an androgen agent for growing hair on the human body and increasing vitality in males.
It is an established theory that the growth of all body hair such an eyebrows, mustaches, and underarm hair, ex-cluding hair on the head is primarily controlled by androgens and does not grow very long. Further hair on the head is primarily controlled by estrogens and grows to great lengths.
It is also known that while there are baldheaded men there are few baldheaded women from natural causes. Further the reason why body hair is thick on males and thin on females is explainable by such hormonal action. In addition, it is also well known that male vitality can be increased by replenishing androgens.
As such, several agents for growing body hair consis--ting mainly of androgens have been marketed. However, all such agents cause skin inflammation.
Medical treatments have often been carried out to enhance the vitality of males by injecting high-ur,i-ts of andro-gen or by topical application. It is however now cornmon that strong adverse side effects occur in injection of the high-unit androgens and topical application thereof causes skin inflam-mation.
Further, by using androgens for both body hair growth and as vitality increasing agents, an effect is recognized because highly concentrated androgen agents are used. Ilowever, adverse side effects or skin inflammation due to the high con-centration of the androgen is inevitable.
The present invention provides an androgen agent w'nich has an excellent effect in increasing a body hair growth in humans and vitality in males with no significant adverse side effects and causes no significant skin inflammation as the androgen is Fed into the skin.
- 1 - ,~r~
~2 5~3 ~
According to the present invention therefore -there is ; provided an androgen agent for dermatological application for growing hair on the human body and/or increasirlg its vitality which cornprises per 100 9 of an ointment base up to 20 mg of androgen; up to 20 nlg of an adrenocortical hormone and up to 20 mg of vitamin B2.
The present invention is based on the concept that androgen is a generic nalne for hormones, in particular testosterone, secreted from the testicles which promote the growth of the male reproductive organs and has secondary sexual character, namely they have an androgenic activity. Testoster-one propionate, methyltestosterone and Fluoxymesterone are synthetic derivatives of testerone and all have androgen activity.
It is now considered by the inventor that the androgen has a body hair generating activity as well as the androgen activity described above. Thus body hair generation is a live body phenomenon controlled by androgens in the cutaneous tissue system, and is required for hair to grow from proteins to arrange to cultivating conditions while maintaining the normal living conditions of the cutaneous tissue system.
As in my prior invention as disclosed in my copending Canadian Patent Application Serial No. 459,176 which is directed to the development of hair on the head I have found tha-t the following three conditions are required for the development of hair on the body; (1) not only to replenish androgen to -the body, but also to reduce the concentration of androgen until no skin inflarnmation occurs and there are no other bad side effects due to its accumulation in the body; (2) to reduce the inflam-matory action of the androgen by the action of andrenocortical hormone; and (3) to apply~the metabolism of vitamirl B2 to the grow-th of hair from protein. I-t has thus been found when an ' ~ S ~3~ ~
androgen agent satisfying these three conditions is applied to the skin to generate hair on the body, that good hair develop-ment occurs with no skin inflammation.
For replenishing androgen onto the skin For enhancing . male vitality, it has been found that such an effect occurs without adverse side effects and without skin inflalnmation, when the conditions under which androgen acts is as aforesaid for hair development on the human body namely healthy living condi-tions of -the skin tissue. The androgen agent was evaluated by deterlnining the development of pubes as well as by investiga-ting the increase vitality of males by applying the androgen agent locally to the skin of a male. It was found -that the agent is very good in enhancing vitality with no adverse side effects and skin inflammation.
Adrenocortical hormones are hormones secreted from the adrenal cortex including prednisolone acetate, cortisone acetate, hydrocortisone acetate, methylprednisolone acetate, and prednisolone sodium succinate, all of which, excep-t aldosterone, have antiphlogistic action.
In one embodiment of the present invention an androgen agent for use in growing body hair and increasing vitality in males according to the present invention is prepared by uni~
formly distributing 1 mg of testosterone propionate (androgen), 1.1 mg of prednisolone acetate (andrenocortical hormone), 0.5 mg of riboflavine phosphate (vitamin B2 compound), 0.01 mg of falvine-adenine dinucleotide (vitarnin B2 compound), 0.3 mg of chlorophenylamine maleate, 1.0 mg of pyridoxine hydrochloride,
2.0 mg of nicotinamide, 1.0 mg of panthothenyl alcohol and 4.0 mg of DL-methionine, 100 g of an ointment base. For such pre-paration, an ampoule for the injection of each component was used. For example, for t~he testosterone propionate, 10 mg (1 cc) of injec-tion liquid containing 0.1 cc of testosterone 3B~
propionate was used. Also for each of the ingredients, 2 cc o-f ; injection liquid were used and the injection liquid is an oily or aqueous liquid.
In a second embodiment in a similar manner as in the first embodiment, an androgen agent was made up except -that cortisone acetate (adrenocortical hormone) was used instead of the prednisolone acetate.
In a third embodiment in a similar manner as in the first embodiment an androgen agent was made up except that 1 mg of testosterone enanthate was used instead of the -testos-terone propionate. For the testosterone enanthate, an equivalent quanti-ty corresponding to 1/125 of 125 mg (lcc) injection liquid was used.
In the application of the aforesaid androgen agent according to the present invention, no skin inflamlnation occurs and nothing is accumulated in the skin, since the main com-ponent, i.e. the testosterone propionate (androgen) is present in the ultra-low concentration of 0.001 percent.
The prednisolone acetate (adrenocortical hormone) suppresses the inflammatory action of the androgen, and vitamin B2 compound (riboflavine phosphate and flavine-aden-ine dinu-cleotide) promotes the growth of body hair and enhances the vitality activity because it also promotes the metabolism of proteins in the healthy living conditions of cutaneous -tissue.
Heretofore the actions of the androgen, adrenocortical hormone and vitamin B2 which is postulated play leading roles in the effect of agent of the present invention have been given the other components it is believed also play supporting roles in -the effec-t of enhancement of hair growth and vitality of the agent of the present invention. It is believed that chloro-phenylamine maleate enhances the action of adrenocortical hor-mone and pyridoxine hydrochloride, nicotinamide, pantho-thenyl ~ L~2563~3~
alcohol, and DL-me-thionine promote respectively the development of body hair and the increase in vitality by enhanc-ing -the protein metabolism of vitamin B2.
Fur-ther, it has been found that when the agent according to the invention is applied for example to the hair roots of eyebrows, eyelashes grow substantially or when it is applied to a man's pudenda, -there is seen an increase in vitality and hair generation in both feet. This means that the agent according to the invention has its effect on other locations of the body than the location on which it was applied due to absorption into the body.
The concentration of the androgen agent according to the invention is 1 mg of the androgen in 100 9 o-f -the ointment base, i.e. 0.001 percent and is more concentrated than the concen-tration of the estrogen of 0.2 mg in 4 litres of distilled water, namely 0.000005 percent according to the invention of my aforesaid copending Canadian application. Therefore there was no fundamental to consider the accumulation of estrogens for such hair development agent. However the androgen agents according to the present invention should not be used in a wide range and over a long period of time without considering the accumulation of the androgen.
It has been found that the androgen agen-t according to the present invention has absolutely no adverse side effects and causes no skin inflammation whilst providing For the substantial development of hair on the human body and increase in vitality of males.
The androgen agent according to the present invention may be used for hair generation by rubbing it into an area where hair development is desired or for vitality enhancement by locally rubbing it into t~he skin.
The eFfects of the androgen agent of the present .~ 3~
~;
inven-tion are given hereafter.
(1 ) A woman 45 years old applied a cupful of the agent with an earpick once a day and felt i-tching at the applied location.
After approximately one month, it was seen that hair was generated on her eyebrows and at the same time her eyelashes grew. She nad continued the application for four months with no discernable skin inflammation.
(2) A man 55 years old applied the agent in an amount the size of a bean to his pudenda once a day for approximately three years. It was found that his pubic hair developed and the hair simultaneously grew on both his feet. Further when the quantity of agent at each application was increased, he complained of a dull pain in his testicles. However he felt no dull pain with the similar quantity of agent and had no discernable skin inflammation during the three years of application.
propionate was used. Also for each of the ingredients, 2 cc o-f ; injection liquid were used and the injection liquid is an oily or aqueous liquid.
In a second embodiment in a similar manner as in the first embodiment, an androgen agent was made up except -that cortisone acetate (adrenocortical hormone) was used instead of the prednisolone acetate.
In a third embodiment in a similar manner as in the first embodiment an androgen agent was made up except that 1 mg of testosterone enanthate was used instead of the -testos-terone propionate. For the testosterone enanthate, an equivalent quanti-ty corresponding to 1/125 of 125 mg (lcc) injection liquid was used.
In the application of the aforesaid androgen agent according to the present invention, no skin inflamlnation occurs and nothing is accumulated in the skin, since the main com-ponent, i.e. the testosterone propionate (androgen) is present in the ultra-low concentration of 0.001 percent.
The prednisolone acetate (adrenocortical hormone) suppresses the inflammatory action of the androgen, and vitamin B2 compound (riboflavine phosphate and flavine-aden-ine dinu-cleotide) promotes the growth of body hair and enhances the vitality activity because it also promotes the metabolism of proteins in the healthy living conditions of cutaneous -tissue.
Heretofore the actions of the androgen, adrenocortical hormone and vitamin B2 which is postulated play leading roles in the effect of agent of the present invention have been given the other components it is believed also play supporting roles in -the effec-t of enhancement of hair growth and vitality of the agent of the present invention. It is believed that chloro-phenylamine maleate enhances the action of adrenocortical hor-mone and pyridoxine hydrochloride, nicotinamide, pantho-thenyl ~ L~2563~3~
alcohol, and DL-me-thionine promote respectively the development of body hair and the increase in vitality by enhanc-ing -the protein metabolism of vitamin B2.
Fur-ther, it has been found that when the agent according to the invention is applied for example to the hair roots of eyebrows, eyelashes grow substantially or when it is applied to a man's pudenda, -there is seen an increase in vitality and hair generation in both feet. This means that the agent according to the invention has its effect on other locations of the body than the location on which it was applied due to absorption into the body.
The concentration of the androgen agent according to the invention is 1 mg of the androgen in 100 9 o-f -the ointment base, i.e. 0.001 percent and is more concentrated than the concen-tration of the estrogen of 0.2 mg in 4 litres of distilled water, namely 0.000005 percent according to the invention of my aforesaid copending Canadian application. Therefore there was no fundamental to consider the accumulation of estrogens for such hair development agent. However the androgen agents according to the present invention should not be used in a wide range and over a long period of time without considering the accumulation of the androgen.
It has been found that the androgen agen-t according to the present invention has absolutely no adverse side effects and causes no skin inflammation whilst providing For the substantial development of hair on the human body and increase in vitality of males.
The androgen agent according to the present invention may be used for hair generation by rubbing it into an area where hair development is desired or for vitality enhancement by locally rubbing it into t~he skin.
The eFfects of the androgen agent of the present .~ 3~
~;
inven-tion are given hereafter.
(1 ) A woman 45 years old applied a cupful of the agent with an earpick once a day and felt i-tching at the applied location.
After approximately one month, it was seen that hair was generated on her eyebrows and at the same time her eyelashes grew. She nad continued the application for four months with no discernable skin inflammation.
(2) A man 55 years old applied the agent in an amount the size of a bean to his pudenda once a day for approximately three years. It was found that his pubic hair developed and the hair simultaneously grew on both his feet. Further when the quantity of agent at each application was increased, he complained of a dull pain in his testicles. However he felt no dull pain with the similar quantity of agent and had no discernable skin inflammation during the three years of application.
(3) A woman ~0 years old had no pubic hair on her vulva. The androgen agent according to the invention was applied directly to her vulva and pubic hair grew in about three months.
Claims (5)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. An androgen agent for dermatological application for growing hair on the human body and/or increasing its vitality which comprises per 100 g of an ointment base up to 20 mg of an androgen; up to 20 mg of an adrenocortical hormone and up to 20 mg of vitamin B2.
2. An agent according to claim 1, in which the androgen is selected from testosterone, testerone enanthate, testosterone propionate, methyl testosterone and fluoxymesterone and the adrenocortical hormone is selected from prednisolone acetate, cortisone acetate, hydrocortisone acetate, methyl-prednisolone acetate, and prednisolone sodium succinate.
3. An agent according to claim 1, in which the androgen is testosterone propionate, testosterone enanthate and the adrenal cortisone is selected from predisolone acetate and cortisone acetate and the vitamin B2 is selected from riboflavine phosphate and flavine-adenine dinucleotide.
4. An agent according to claim 3 which also contains chlorophenylamine maleate, pyridoxine hydrochloride, pantho-thenyl alcohol and DL-methionine in amounts up to 4 mg/100 g of ointment base.
5. A method of growing hair on a human being which comprises topically applying to the skin an agent according to claim 1, 2 or 3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59257457A JPS61137820A (en) | 1984-12-07 | 1984-12-07 | Male hormone blended agent for application |
| JP59-257457 | 1984-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1256380A true CA1256380A (en) | 1989-06-27 |
Family
ID=17306594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000496832A Expired CA1256380A (en) | 1984-12-07 | 1985-12-04 | Andreogen agent for application to the skin for body hair growth and enhancement of vitality in males |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS61137820A (en) |
| CA (1) | CA1256380A (en) |
| DE (1) | DE3538612A1 (en) |
| FR (1) | FR2574293A1 (en) |
| GB (1) | GB2167957B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0256472A3 (en) * | 1986-08-11 | 1988-09-07 | Lion Corporation | Cosmetic agent for application to skin |
| EP1806131A3 (en) | 1996-07-22 | 2007-08-01 | Renovo Limited | Use of sex steroid function modulators to treat wounds and fibrotic disorders |
| AU7250301A (en) * | 2000-06-22 | 2002-01-02 | Willy Ben Moussa Ben Mohammed | Use of glucocorticosteroids for producing a medicament to treat oligotrichia |
| IL157535A0 (en) * | 2003-08-21 | 2004-03-28 | Topimed Ltd | Preparations for the prevention of skin atrophy |
| WO2006084312A1 (en) * | 2005-02-09 | 2006-08-17 | Acrux Dds Pty Ltd | Method of promoting hair growth |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2257223A1 (en) * | 1972-11-22 | 1974-06-12 | Fouad Dr Med Talabani | Hair growth and anti- hairloss compsn. - contg. mixts of androgen, oestrogen, corticoid and carriers |
| JPS5879913A (en) * | 1981-11-09 | 1983-05-13 | Taizo Ayukawa | Hair tonic composition |
| JPS5988407A (en) * | 1982-11-11 | 1984-05-22 | Shiseido Co Ltd | Hair tonic |
| JPS59172412A (en) * | 1983-03-19 | 1984-09-29 | Shiseido Co Ltd | Hair tonic |
-
1984
- 1984-12-07 JP JP59257457A patent/JPS61137820A/en active Pending
-
1985
- 1985-10-30 DE DE19853538612 patent/DE3538612A1/en not_active Withdrawn
- 1985-12-03 FR FR8517865A patent/FR2574293A1/en not_active Withdrawn
- 1985-12-04 GB GB08529933A patent/GB2167957B/en not_active Expired
- 1985-12-04 CA CA000496832A patent/CA1256380A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE3538612A1 (en) | 1986-06-19 |
| GB8529933D0 (en) | 1986-01-15 |
| FR2574293A1 (en) | 1986-06-13 |
| GB2167957B (en) | 1988-12-14 |
| JPS61137820A (en) | 1986-06-25 |
| GB2167957A (en) | 1986-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Price | Testosterone metabolism in the skin: a review of its function in androgenetic alopecia, acne vulgaris, and idiopathic hirsutism including recent studies with antiandrogens | |
| Punnonen | Effect of castration and peroral estrogen therapy on the skin | |
| US5629002A (en) | Cosmetic or pharmaceutic preparations for improving hair quaility and stimulating growth of the hair | |
| Taurog et al. | The role of TRH in the neoteny of the Mexican axolotl (Ambystoma mexicanum) | |
| US20060069036A1 (en) | Methods of treatment of inflammation using glutathiones | |
| US20100317631A1 (en) | Gel Composition and Transcrotal Application of a Composition for the Treatment of Hypogonadism | |
| Gomez et al. | Effect of 13-cis-retinoic acid on the hamster flank organ | |
| CA1256380A (en) | Andreogen agent for application to the skin for body hair growth and enhancement of vitality in males | |
| CA1226524A (en) | Pharmaceutical composition for the treatment of hair loss | |
| US5094857A (en) | Treatment of acne or androgenetic alopecia by topical administration of ethisterone | |
| Wheeler et al. | The effects of topically applied hormones on growth, pigmentation and keratinization of the nipple and areola | |
| Peter | Nature, localization and actions of neurohormones regulating gonadotropin secretion in teleosts | |
| MIYAKE et al. | Hormonal influences on the carbonic anhydrase concentration in the accessory reproductive tracts of the rat | |
| EP1253966B1 (en) | Substances and agents for positively influencing collagen | |
| Speert | Local action of sex hormones | |
| US6204258B1 (en) | Method of treating alopecia | |
| US4272508A (en) | Cosmetics for treatment of hair and skin | |
| Hall et al. | Hormonal control of hamster ear sebaceous gland lipogenesis | |
| Peters et al. | The effect of danazol on the pituitary function, thyroid function, and mastodynia | |
| Tamm et al. | The effect of orally administered cyproterone on the sebum production in human subjects | |
| EP1006996B1 (en) | USE OF 17-$g(a)-ESTRADIOL FOR THE TREATMENT OF AGED OR SUNDAMAGED SKIN AND/OR SKIN ATROPHY | |
| Ebling | The response of the cutaneous glands to steroids | |
| Neumann | Pharmacology and clinical use of antiandrogens: a short review | |
| Batra et al. | Effect of estrogen treatment on the peroxidase activity and estrogen receptors in the female rabbit urogenital tissues | |
| Kitawaki et al. | Induction of estradiol dehydrogenase activity in human uterine endometrium by synthetic steroids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |